Đăng xuất
Fertility: If ibuprofen is administered to a woman wishing to become pregnant, the dose should be as low as possible and the duration of treatment as short as possible.
Pregnancy: Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryonal/foetal development. Data from epidemiological studies indicate an increased risk of miscarriage, fetal cardiac malformations and gastroschisis following use of prostaglandin synthesis inhibitors in early pregnancy. The absolute risk for cardiovascular malformations increased from less than 1% to approximately 1.5%. The risks increased with increasing dose and duration of treatment. In animals, use of prostaglandin synthesis inhibitors has been shown to increase pre- and post-implantation loss and embryonic mortality. In addition, increased incidences of other malformations, including cardiovascular, have been reported in animals treated with prostaglandin synthesis inhibitors during organogenesis. During the first and third trimesters of pregnancy, ibuprofen should not be used unless clearly necessary. If ibuprofen is used in a woman trying to conceive or in the first and second trimesters of pregnancy, the dose should be kept as low and the duration of treatment as short as possible.
From the 20th week of pregnancy onwards, the use of ibuprofen may cause oligohydramnios due to fetal renal dysfunction. This may occur soon after starting treatment and is usually reversible on discontinuation of treatment. In addition, there have been reports of ductus arteriosus constriction following treatment in the second trimester, but most resolved after discontinuation of treatment. Therefore, ibuprofen should not be used during the first and second trimesters unless clearly necessary. If ibuprofen is used in a woman trying to conceive or in the first and second trimesters of pregnancy, the lowest effective dose should be used for as short a period as possible. Consider antenatal monitoring for oligohydramnios and ductus arteriosus after ibuprofen use for several days from the 20th week of pregnancy onwards. Ibuprofen should be discontinued if oligohydramnios or ductus arteriosus is detected.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may cause the following adverse effects in the fetus: Cardiopulmonary toxicity (constriction/premature closure of the ductus arteriosus and pulmonary hypertension); Renal dysfunction.
In the mother and newborn, during late pregnancy: May prolong bleeding time, antiplatelet effects may occur even at very low doses.
Inhibition of uterine contractions leading to delay or prolongation of labor.
Ibuprofen is therefore contraindicated during the third trimester of pregnancy.
Lactation: Ibuprofen and its breakdown products/metabolites pass into breast milk. However, no effect on newborns/breastfed infants is expected when ibuprofen, granules for oral solution in sachet-dose is administered at therapeutic doses. As the harmful effects on the infant are still unknown, it is generally not necessary to interrupt breast-feeding in the event of short-term treatment at the recommended dose in the event of pain and mild to moderate fevers.
